Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

FDA approves new maintenance therapy for recurrent cancers

The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.

27 Mar 2017

Ionis announces FDA approval of first SMA drug in the U.S for pediatric and adult patients

Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has approved SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

26 Dec 2016

FDA awards accelerated approval to new ovarian cancer drug

The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer.

19 Dec 2016

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.

17 Oct 2016

Study finds blood thinning drugs derived from cattle and pigs have equivalent anti-clotting properties

As demand for the widely used blood thinning drug heparin continues to grow, experts worry of possible shortages of the essential medication.

6 Oct 2016

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.

29 Aug 2016

Report: Zika cases soar in Puerto Rico

As of July 7, Zika has been diagnosed in 5,582 people, including 672 pregnant women, in Puerto Rico according to a new report published today in the Morbidity and Mortality Weekly Report (MMWR).

30 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Salvage inotuzumab ozogamicin improves ALL outcomes

Compared with standard chemotherapy, treatment with inotuzumab ozogamicin increases the rate of complete remission and allows a higher proportion of patients with relapsed or refractory acute lymphoblastic leukaemia to subsequently receive stem-cell transplantation, research suggests.

22 Jun 2016

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia.

15 Jun 2016

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

We recently discovered a new form of an inherited deficiency of platelets, which is caused by mutations in the ETV6-gene.

13 Jun 2016

Air pollution exposure may have direct role in triggering lupus among children and adolescents

The results of a study presented today at the European League Against Rheumatism Annual Congress show for the first time that an individual's exposure to air pollution may have a direct role in triggering disease activity as well as airway inflammation in children and adolescents with Systemic Lupus Erythematosus (SLE).

10 Jun 2016

Unsafe antiplatelet use persists in PCI patients

Contraindicated antiplatelet use is rare but persists in patients undergoing percutaneous coronary intervention, show US study data.

8 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.

18 May 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.

18 Apr 2016

Magnesium could be safe, cost-effective therapeutic intervention for genetic coagulation disorder

An international team of scientists was able to demonstrate in mouse and patient studies, how magnesium affects the production of blood platelets and that the TRPM7 channel function plays a key role in this process. Scientists of the Rudolf Virchow Center and the Hospital of the University of Würzburg were primarily involved in this study. Their results were published in the current journal "Nature Communications".

4 Apr 2016

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).

7 Mar 2016